## Junan Li

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7363456/publications.pdf

Version: 2024-02-01

		687363	361022
39	1,298	13	35
papers	citations	h-index	g-index
39	39	39	2585
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Ankyrin Repeat: A Unique Motif Mediating Proteinâ^'Protein Interactionsâ€. Biochemistry, 2006, 45, 15168-15178.	2.5	537
2	Regulatory Mechanisms of Tumor Suppressor P16 <sup>INK4A</sup> and Their Relevance to Cancer. Biochemistry, 2011, 50, 5566-5582.	2.5	251
3	Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Scientific Reports, 2015, 5, 12122.	3.3	58
4	Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy. Nature Communications, 2021, 12, 7264.	12.8	55
5	Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer. Nano Research, 2019, 12, 855-861.	10.4	39
6	Polymorphism in <i>ANRIL</i> is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Molecular Carcinogenesis, 2017, 56, 1722-1732.	2.7	28
7	Dissection of CDK4-Binding and Transactivation Activities of p34SEI-1and Comparison between Functions of p34SEI-1and p16INK4Aâ€. Biochemistry, 2005, 44, 13246-13256.	2.5	25
8	A Structurally Optimized Celecoxib Derivative Inhibits Human Pancreatic Cancer Cell Growth. Journal of Gastrointestinal Surgery, 2006, 10, 207-214.	1.7	25
9	Gankyrin, a biomarker for epithelial carcinogenesis, is overexpressed in human oral cancer. Anticancer Research, 2011, 31, 2683-92.	1.1	25
10	Frequent p16INK4A/CDKN2A alterations in chemically induced Syrian golden hamster pancreatic tumors. Carcinogenesis, 2003, 25, 263-268.	2.8	21
11	Increased complement activation during platelet storage. Transfusion, 2017, 57, 2182-2188.	1.6	21
12	Microneedle-Based Delivery of Amphotericin B for Treatment of Cutaneous Leishmaniasis. Biomedical Microdevices, 2019, 21, 8.	2.8	18
13	Genetic alterations of <i>RD</i> <sup><i>INK4/ARF</i></sup> enhancer in human cancer cells. Molecular Carcinogenesis, 2014, 53, 211-218.	2.7	15
14	Synthesis and antileishmanial evaluation of thiazole orange analogs. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126725.	2.2	14
15	Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies. Leukemia and Lymphoma, 2018, 59, 2377-2382.	1.3	13
16	Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience. Leukemia and Lymphoma, 2019, 60, 2223-2229.	1.3	12
17	Pharmacokineticâ€Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving Highâ€Dose Melphalan for Autologous Stem Cell Transplant. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 748-758.	2.5	11
18	Tumor suppressor <i>p16</i> <sup><i>INK4A</i></sup> / <i>Cdkn2a</i> alterations in 7, 12â€dimethylbenz(a)anthracene (DMBA)â€induced hamster cheek pouch tumors. Molecular Carcinogenesis, 2008, 47, 733-738.	2.7	10

#	Article	IF	CITATIONS
19	Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	10
20	A Single Nucleotide Polymorphism in <i>SLC7A5</i> Was Associated With Clinical Response in Multiple Myeloma Patients. Anticancer Research, 2019, 39, 67-72.	1.1	10
21	Alterations in RD INK4/ARF -mediated en bloc regulation of the INK4-ARF locus in human squamous cell carcinoma of the head and neck. Molecular Carcinogenesis, 2015, 54, 532-542.	2.7	9
22	CRISPR/Cas9 Genome Editing of the Human Topoisomerase II <i>i²±</i> i>Intron 19 5′ Splice Site Circumvents Etoposide Resistance in Human Leukemia K562 Cells. Molecular Pharmacology, 2021, 99, 226-241.	2.3	9
23	Expression and characterization of Syrian golden hamster p16, a homologue of human tumor suppressor p16INK4A. Biochemical and Biophysical Research Communications, 2003, 304, 241-247.	2.1	8
24	Age-dependent accumulation of mitochondrial DNA deletions in the aortic root of atherosclerosis-prone apolipoprotein E-knockout mice. Archives of Gerontology and Geriatrics, 2016, 63, 72-77.	3.0	8
25	A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine. Journal of Oncology Pharmacy Practice, 2018, 24, 290-298.	0.9	8
26	PTC209, a Specific Inhibitor of BMI1, Promotes Cell Cycle Arrest and Apoptosis in Cervical Cancer Cell Lines. Anticancer Research, 2020, 40, 133-141.	1.1	8
27	Deletion of RDINK4/ARF enhancer: A novel mutation to "inactivate―the INK4-ARF locus. DNA Repair, 2017, 57, 50-55.	2.8	7
28	XRCC1â€mediated DNA repair is associated with progressionâ€free survival of multiple myeloma patients after autologous stem cell transplant. Molecular Carcinogenesis, 2019, 58, 2327-2339.	2.7	7
29	Educating Pharmacy Students About Underserved Populations Using Patient Speakers and Simulation Activities. American Journal of Pharmaceutical Education, 2021, 85, 8461.	2.1	6
30	Gankyrin Oncoprotein: Structure, Function, and Involvement in Cancer. Current Chemical Biology, 2010, 4, 13-19.	0.5	5
31	Coordinated expression of cyclin-dependent kinase-4 and its regulators in human oral tumors. Anticancer Research, 2014, 34, 3285-92.	1.1	5
32	G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. Leukemia and Lymphoma, 2017, 58, 2947-2951.	1.3	4
33	Quantification of miRNAs Co-Immunoprecipitated with Argonaute Proteins Using SYBR Green-Based qRT-PCR. Methods in Molecular Biology, 2018, 1680, 29-40.	0.9	4
34	Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. Anticancer Research, 2020, 40, 5707-5713.	1.1	4
35	A Single Nucleotide Polymorphism (SNP) in the <i>SLC22A3</i> Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy. Anticancer Research, 2022, 42, 385-395.	1.1	4
36	Synthesis and Antileishmanial Evaluation of Arylimidamide–Azole Hybrids Containing a Phenoxyalkyl Linker. ACS Infectious Diseases, 2021, 7, 1901-1922.	3.8	3

#	Article	IF	CITATIONS
37	Antiemetic medication efficacy during EPOCH and R-EPOCH treatment. Journal of Oncology Pharmacy Practice, 2020, 27, 107815522096772.	0.9	1
38	Cisplatin Induced the Expression of SEI1 (TRIP-Br1) Oncogene in Human Oral Squamous Cancer Cell Lines. Anticancer Research, 2020, 40, 67-73.	1.1	0
39	Efficacy of Once-Weekly Bortezomib with Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2018, 132, 1958-1958.	1.4	0